In April 2026, Gyre initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled. The trial is evaluating pirfenidone for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results